Knight Therapeutics Inc.

OTC
KHTRF
paper.types.company
Rentabilité sur six mois: +11.82%
Rendement en dividendes: 0%
Secteur: Healthcare

4.17 $

0 $ 0%
3.59 $
4.55 $

paper.min_max_per_year

Calendrier des promotions Knight Therapeutics Inc.

Calendrier avancé Graphique simple
Financial Markets by TradingView

À propos de l'entreprise Knight Therapeutics Inc.

Knight Therapeutics Inc. develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide.

plus de détails
It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma. The company also provides Ladevina for multiple myeloma and myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Rembre for chronic myeloid leukemia; Palbocil for breast cancer; Ambisome and Cresemba for fungal infection; Impavido for leishmaniasis; Dolufevir for HIV infection; Exelon for dementia; and Ibsrela for irritable bowel syndrome with constipation. In addition, it offers Salofalk for ulcerative colitis; Ursofalk for biliary cirrhosis; Imvexxy for moderate to severe dyspareunia; Bijuva for vasomotor symptoms; Fibridoner for idiopathic pulmonary fibrosis; Toliscrin DPI for pseudomonas aeruginosa lung infection; Toliscrin 1-2 for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections. Further, it finances other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is headquartered in Montreal, Canada.
Ajouter à la liste de comparaison
Ajouter à la liste de surveillance
Ajouter au portefeuille
Ajouter un avis de prix

Paramètres de base

Industry
Biotechnology
Sector
Health Care
Валюта
usd
Валюта отчета
usd
Сайт
lien
Tous les paramètres

Grade

Sous-estimation
Nom Signification Grade
P/S 1.42 9
P/BV 0.6617 10
P/E 121.45 1
Efficacité
Nom Signification Grade
ROA 0.3909 1
ROE 0.4855 1
ROIC 0 0
Dividendes
Nom Signification Grade
Rendement en dividendes 0 0
DSI 0 0
Croissance moyenne du dividende 0 0
Devoir
Nom Signification Grade
Debt/EBITDA 0.7694 9
Debt/Ratio 0.0514 10
Debt/Equity 0.2121 10
Impulsion de croissance
Nom Signification Grade
Rentabilité Revenue, % 43.39 6
Rentabilité Ebitda, % 73.13 8
Rentabilité EPS, % -86.32 0
Plus de détails

paper.price.prices

Prix Common.min. Common.max. Changement paper.changes_in_industry paper.changes_in_index
common.calendar.number_days.1 4.17 $ 0 $ 0 $ 0 % 0 % 0 %
common.calendar.number_days.7d 4.46 $ 0 $ 0 $ -6.48 % 0 % 0 %
common.calendar.number_days.30d 4.27 $ 4.17 $ 4.46 $ -2.41 % 0 % 0 %
common.calendar.number_days.90d 3.88 $ 3.95 $ 4.46 $ 7.58 % 0 % 0 %
common.calendar.number_days.180d 3.73 $ 3.59 $ 4.46 $ 11.82 % 0 % 0 %
common.calendar.number_days.1y 4.4 $ 3.59 $ 4.55 $ -5.2 % 0 % 0 %
common.calendar.number_days.3y 4.18 $ 3.19 $ 4.71 $ -0.22 % 0 % 0 %
common.calendar.number_days.5y 5.58 $ 3.19 $ 5.38 $ -25.25 % 0 % 0 %
common.calendar.number_days.10y 0 $ 3.19 $ 8.33 $ 0 % 0 % 0 %
common.calendar.number_days.ytd 3.73 $ 3.61 $ 4.46 $ 11.82 % 0 % 0 %

Principaux propriétaires

Entreprises similaires

P/E & P/BVEV/Ebitda & Debt/Ebitda


Gestion d'entreprise

Superviseur Titre d'emploi Paiement Année de naissance
Mr. Jonathan Ross Goodman B.A., L.L.B., M.B.A. Executive Chairman 182.71k 1969 (56 années)
Ms. Samira Sakhia BCom, CA, CPA, MBA President, CEO & Director 490.95k 1968 (57 années)
Mr. Arvind Utchanah Chief Financial Officer 442.12k
Ms. Amal Khouri B.Sc., M.B.A. Chief Business Officer 378.51k
Mr. Jeff Martens Global Vice President of Commercial 306.09k
Mr. Stephani Saverio Vice President of Business Development 320.84k
Mr. Leopoldo Bosano Vice-President of Manufacturing & Operations N/A
Ms. Monica Percario Global Vice President of Scientific Affairs N/A
Mr. Henrique Dias Global Director of Marketing N/A
Ms. Susan Caroline Emblem Global Vice President of Human Resources N/A

Informations sur l'entreprise

Adresse: Canada, Montreal. QC HZ B, 3400 de Maisonneuve Boulevard West - Ouvrir dans google maps, Ouvrir les cartes yandex
Site web: https://www.gud-knight.com